Explore the latest in cancer biomarkers, including advances in identifying precision markers for selecting treatment and predicting outcomes.
This study examines HER2 ISH-equivocal breast cancers to asses 2013/2014 American Society of Clinical Oncology and College of American Pathologists guidelines in determining HER2-positive or HER2-negative breast cancers and false-positive results.
This validation study investigates the use of circulating protein biomarkers to improve lung cancer risk assessment and eligibility criteria for screening with low-dose computed tomography.
This prospective cohort study evaluates the 5-year risk of cervical precancer following p16/ki-67 dual-stain triage of HPV-positive women.
This diagnostic study investigates whether nuclear ZEB2 expression in colorectal cancer is associated with early recurrence and reduced survival in 2 independent patient cohorts.
This phase 2 clinical trial investigates the safety and efficacy of BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen, for treating patients with metastatic castration-resistant prostate cancer.
This phase 1 study evaluates the safety, clinical activity, and biomarkers associated with the use of single-agent atezolizumab in women with metastatic triple-negative breast cancer.
This randomized clinical trial evaluates the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy for a duration of 9 weeks vs 1 year in women with HER2-positive early breast cancer treated with up-front chemotherapy containing a taxane and trastuzumab.
This single-arm, open-label trial evaluates the safety and efficacy of the anti–epidermal growth factor receptor antibody panitumumab plus neoadjuvant chemotherapy (nab-paclitaxel and carboplatin followed by fluorouracil, epirubicin, and cyclophosphamide) in patients with primary HER2-negative inflammatory breast cancer.
This cohort study examines whether an assay for the nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells can be used to estimate overall survival among patients with metastatic castration-resistant prostate cancer treated with taxanes vs androgen receptor signaling inhibitors.
This clinical trial investigates the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.
This secondary analysis of tumor specimens collected for the LUX-Lung 8 randomized clinical trial assesses whether ERBB gene mutations of family members were associated with outcomes among patients with lung squamous cell carcinoma randomized to treatment with afatinib or erlotinib.
This tumor database study examines the prevalence of PDL1 amplification and its utility as a response biomarker to PD-1/PD-L1 blockade in solid tumors.
This systematic review and meta-analysis examines the diagnostic accuracy of volatile organic compound (VOC)–based exhaled breath tests for cancer and the challenges and strategies inherent in the use of breath testing for cancer diagnosis.
This cohort study determines whether circulating tumor cell status is associated with radiotherapeutic benefit in terms of overall, local recurrence-free, and disease-free survival in patients with early-stage breast cancer.
This secondary analysis of a randomized clinical trial investigates the association of circulating tumor cells with recurrence of breast cancer 5 or more years after diagnosis among patients with hormone receptor–positive breast cancer.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: